Evercore ISI Group Upgrades Avidity Biosciences to Outperform, Announces $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Josh Schimmer has upgraded Avidity Biosciences (NASDAQ:RNA) from In-Line to Outperform and set a $20 price target.
May 22, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences (NASDAQ:RNA) has been upgraded to Outperform by Evercore ISI Group, with a $20 price target.
The upgrade from In-Line to Outperform by Evercore ISI Group analyst Josh Schimmer indicates a positive outlook for Avidity Biosciences. The $20 price target suggests potential upside for the stock, which could lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100